Rationale for Antithrombotic Therapy in Atrial Fibrillation

Patients with atrial fibrillation at significant risk for thromboembolism (including those with valvular heart disease, recent congestive heart failure, severe left ventricular dysfunction, prior thromboembolism, cardiac thrombus, or thyrotoxicosis), excluding subjects with lone atrial fibrillation who are less than 60 years of age.

Antithrombotic therapy (anticoagulant therapy such as sodium warfarin, or aspirin)

Thromboembolismhard clinical